Wide Ranks

CLRB

Cellectar Biosciences, Inc.

1.53

Top Statistics
Market Cap 63 M Forward PE -1.81 Revenue Growth 0.00 %
Current Ratio 1.84 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.25 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 25 M Total Cash Per Share 0.6380 Total Debt 530856
Total Debt To Equity 3.86 Current Ratio 1.84 Book Value Per Share -0.9560
All Measures
Short Ratio 834.00 % Message Board Id finmb_37613299 Shares Short Prior Month 2 M
Return On Equity -7.97 City Florham Park Uuid d92a6d57-8c29-3e38-89dc-584b57cac7f0
Previous Close 1.56 First Trade Date Epoch Utc 1 B Book Value -0.9560
Beta 1.01 Total Debt 530856 Volume 199865
Last Split Date 1 B Fifty Two Week Low 1.39 Total Cash Per Share 0.6380
Shares Short Previous Month Date 1 B Target Median Price 12.00 Max Age 86400
Recommendation Mean 1.67 Sand P52 Week Change 0.3133 Target Mean Price 13.33
Net Income To Common -52962856 Short Percent Of Float 0.0506 Implied Shares Outstanding 41 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 824040
Average Volume10days 824040 Total Cash 25 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0284 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 1.56 Target Low Price 7.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.99 Open 1.57
Free Cashflow -20477556 State NJ Dividend Yield 0.00 %
Return On Assets -1.66 Time Zone Short Name EST Trailing Eps -1.41
Day Low 1.52 Address1 100 Campus Drive Shares Outstanding 41 M
Price Hint 4 Target High Price 21.00 Website https://www.cellectar.com
52 Week Change -0.3806 Average Volume 323676 Forward Eps -2.83
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 170.50 %
Last Split Factor 1:10 Regular Market Day High 1.61 Is_sp_500 False
Profit Margins 0.00 % Debt To Equity 3.86 Fifty Two Week High 4.45
Day High 1.61 Shares Short 1 M Regular Market Open 1.57
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.0452 Operating Cashflow -45166224 Currency USD
Time Zone Full Name America/New_York Market Cap 63 M Is_nasdaq_100 False
Zip 07932 Quote Type EQUITY Industry Biotechnology
Long Name Cellectar Biosciences, Inc. Regular Market Day Low 1.52 Held Percent Institutions 0.3455
Current Price 1.53 Enterprise To Ebitda -1.25 Financial Currency USD
Current Ratio 1.84 Industry Disp Biotechnology Number Of Analyst Opinions 3
Country United States Float Shares 29 M Two Hundred Day Average 2.71
Enterprise Value 59 M Forward PE -1.81 Regular Market Volume 199865
Ebitda -47400856 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer.

Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.

The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors.

It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio.

The company was founded in 2002 and is headquartered in Florham Park, New Jersey.